CELU – Celularity Inc.
Celularity Inc.CELU
$0.751Name : Celularity Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $24,369,868.00
EPSttm : -1.69
Celularity Inc.
$0.751
5.63%$0.04
CELU — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.33
Margin Of Safety %
Put/Call OI Ratio
0.49
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
0.74
Target Price
6
Analyst Recom
2
Performance Q
8.01
Upside
-3,012.0%
Beta
0.89
Ticker: CELU
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | CELU | 1.4 | 0.07 | 0.01 | 2561 |
| 2026-10-14 | CELU | 1.31 | 0.07 | 35.62 | 2625 |
| 2026-10-15 | CELU | 1.34 | 0.44 | 0.03 | 3564 |
| 2026-10-16 | CELU | 1.27 | 0.44 | 0.22 | 3593 |
| 2026-10-19 | CELU | 1.15 | 0.57 | 0.01 | 2733 |
| 2026-10-20 | CELU | 1.26 | 0.53 | 0.00 | 2850 |
| 2026-10-21 | CELU | 1.03 | 0.52 | 0.33 | 2907 |
| 2026-10-22 | CELU | 1.05 | 0.52 | 0.69 | 2907 |
| 2026-10-23 | CELU | 0.9601 | 0.52 | 0.25 | 2910 |
| 2026-10-26 | CELU | 0.7333 | 0.49 | 999.99 | 2928 |
| 2026-10-27 | CELU | 0.8 | 0.49 | 1.00 | 2927 |
| 2026-10-28 | CELU | 0.94 | 0.49 | 1.00 | 2927 |
| 2026-10-29 | CELU | 0.8652 | 0.49 | 1.00 | 2929 |
| 2026-10-30 | CELU | 0.8056 | 0.49 | 1.00 | 2929 |
| 2026-11-02 | CELU | 0.8003 | 0.49 | 0.00 | 2949 |
| 2026-11-03 | CELU | 0.8123 | 0.49 | 999.99 | 2949 |
| 2026-11-04 | CELU | 0.818 | 0.49 | 0.00 | 2957 |
| 2026-11-05 | CELU | 0.7301 | 0.49 | 0.00 | 2961 |
| 2026-11-06 | CELU | 0.7638 | 0.49 | 0.00 | 2960 |
| 2026-11-09 | CELU | 0.757 | 0.49 | 0.00 | 2960 |
| 2026-11-10 | CELU | 0.72 | 0.49 | 0.00 | 2960 |
| 2026-11-11 | CELU | 0.7431 | 0.49 | 0.00 | 2960 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | CELU | 1.40 | - | - | - |
| 2026-10-14 | CELU | 1.30 | - | - | - |
| 2026-10-15 | CELU | 1.34 | - | - | - |
| 2026-10-16 | CELU | 1.24 | - | - | - |
| 2026-10-19 | CELU | 1.15 | - | - | - |
| 2026-10-20 | CELU | 1.15 | - | - | - |
| 2026-10-21 | CELU | 1.26 | - | - | - |
| 2026-10-22 | CELU | 1.05 | - | - | - |
| 2026-10-23 | CELU | 0.98 | - | - | - |
| 2026-10-26 | CELU | 0.73 | - | - | - |
| 2026-10-27 | CELU | 0.80 | - | - | - |
| 2026-10-28 | CELU | 0.92 | - | - | - |
| 2026-10-29 | CELU | 0.85 | - | - | - |
| 2026-10-30 | CELU | 0.81 | - | - | - |
| 2026-11-02 | CELU | 0.81 | - | - | - |
| 2026-11-03 | CELU | 0.81 | - | - | - |
| 2026-11-04 | CELU | 0.80 | - | - | - |
| 2026-11-05 | CELU | 0.74 | - | - | - |
| 2026-11-06 | CELU | 0.76 | - | - | - |
| 2026-11-09 | CELU | 0.76 | - | - | - |
| 2026-11-10 | CELU | 0.72 | - | - | - |
| 2026-11-11 | CELU | 0.74 | - | - | - |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | CELU | 0.00 | 0.18 | 7.50 |
| 2026-10-14 | CELU | 0.00 | 0.18 | 7.50 |
| 2026-10-15 | CELU | 0.00 | 0.18 | 7.50 |
| 2026-10-16 | CELU | 0.00 | 0.18 | 7.50 |
| 2026-10-19 | CELU | 0.00 | 0.03 | 3.17 |
| 2026-10-20 | CELU | 0.00 | 0.03 | 3.17 |
| 2026-10-21 | CELU | 0.00 | 0.03 | 3.17 |
| 2026-10-22 | CELU | 0.00 | 0.03 | 3.17 |
| 2026-10-23 | CELU | 0.00 | 0.03 | 3.17 |
| 2026-10-26 | CELU | 0.00 | -0.06 | 3.17 |
| 2026-10-27 | CELU | 0.00 | -0.06 | 3.57 |
| 2026-10-28 | CELU | 0.00 | -0.06 | 3.57 |
| 2026-10-29 | CELU | 0.00 | -0.06 | 3.57 |
| 2026-10-30 | CELU | 0.00 | -0.06 | 3.57 |
| 2026-11-02 | CELU | 0.00 | -0.02 | 3.57 |
| 2026-11-03 | CELU | 0.00 | -0.02 | 3.57 |
| 2026-11-05 | CELU | 0.00 | -0.02 | 3.57 |
| 2026-11-06 | CELU | 0.00 | -0.02 | 3.57 |
| 2026-11-09 | CELU | 0.00 | 0.17 | 3.57 |
| 2026-11-10 | CELU | 0.00 | 0.17 | 3.57 |
| 2026-11-11 | CELU | 0.00 | 0.17 | 4.33 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
0.17
Beta
0.89
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
14
Growth Score
27
Sentiment Score
25
Actual DrawDown %
99.4
Max Drawdown 5-Year %
-99.5
Target Price
6
P/E
Forward P/E
PEG
P/S
1.31
P/B
P/Free Cash Flow
EPS
-1.68
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-248.05
Relative Volume
0.02
Return on Equity vs Sector %
103.9
Return on Equity vs Industry %
123.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
CELU
Healthcare
$0.75
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37
Range 1M
11.3%
Sup Dist
8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
0%
EPS NY
0%
52W%
10.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+700% upside
Upside
+700%
Quality
14
CELU — P/E HistoricalBiotechnology
Celularity Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 115
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
CELU
Latest News
—
Caricamento notizie per CELU…
stock quote shares CELU – Celularity Inc. Stock Price stock today
news today CELU – Celularity Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CELU – Celularity Inc. yahoo finance google finance
stock history CELU – Celularity Inc. invest stock market
stock prices CELU premarket after hours
ticker CELU fair value insiders trading